Spots Global Cancer Trial Database for Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer

Official Title: Correlation of [D10] Phenanthrene Metabolism With Bronchoepithelial Dysplasia and Metaplasia in Smokers at High Risk for Lung Cancer

Study ID: NCT01673711

Conditions

Lung Cancer

Squamous Lung Dysplasia

Tobacco Use Disorder

Interventions

deuterated phenanthrene tetraol

pharmacological study

laboratory biomarker analysis

Study Description

Brief Summary: This clinical trial studies deuterated phenanthrene tetraol in smokers who are at high risk for lung cancer. Studying samples of urine in the laboratory from smokers who are at high risk for lung cancer may help doctors learn more about biomarkers related to cancer.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the relationship between urinary deuterated (\[D10\]) phenanthrene tetraol (PheT) level, PheT:phenanthrols (HOPhe) ratio, and the presence of bronchoepithelial metaplasia and/or dysplasia in smokers who have undergone screening bronchoscopy at Roswell Park Cancer Institute (RPCI). OUTLINE: Patients receive deuterated phenanthrene tetraol orally (PO). Urine samples are collected for laboratory studies for 6 hours after dosing.